EDV-GC

EDV-GC is an investigational **immunomodulatory therapy** consisting of *non-targeted EnGeneIC Dream Vector (EDV) nanocells* loaded with **alpha-galactosylceramide (GC)**, a synthetic glycolipid. It is designed to *boost the immune response*, particularly through the activation of innate and adaptive immunity, to help the body fight cancer. Unlike targeted EDVs, EDV-GC does not have a cancer-specific surface target but delivers its payload to stimulate immune cells such as invariant natural killer T cells (iNKT), dendritic cells, and other components of the immune system. It is commonly studied in combination with targeted nanocell therapies (e.g., E-EDV-D682) and standard chemotherapies (e.g., gemcitabine, nab-paclitaxel) in *advanced and refractory cancers*, most notably **pancreatic ductal adenocarcinoma (PDAC)**[1][3][4][5][7].

Brand names

EDV-GC

Other names

EDV-GCEDV-α-galactosylceramide